GLP-1 Microdosing: What It Is, and What the Evidence Says

"Microdosing" a GLP-1 drug means taking a dose below the lowest FDA-approved starting step — smaller than Wegovy's 0.25 mg or Zepbound's 2.5 mg. It is not a term that appears on either FDA label, and the reason is simple: it is not a use either drug's approval covers.

What people mean by it, and why they try it

The practice is almost always paired with compounded product, since the fixed-dose brand pens don't offer a below-label option — see is compounded GLP-1 legit and safe for how that supply chain works. The stated reasons vary: stretching a supply during a period of shortage, trying to reduce GI side effects, or simply wanting a smaller effect than the full titrated dose produces. All three are understandable motivations. None of them are the same as evidence that it works, or that it's safe.

The finding that actually matters: there is no trial

This is the honest headline, not a caveat buried at the bottom: no randomized controlled trial has tested microdosing for weight loss, glycemic control, or any other outcome. Every efficacy and safety figure either FDA label carries — the STEP 1 and SURMOUNT-1 percentages covered in GLP-1 side effects and GLP-1 dosage and titration schedules — comes from patients dosed on the approved titration schedule, not from doses below it. Below that floor, there is no comparable body of evidence either way.

What the FDA's position actually covers

The FDA has taken enforcement action against compounders continuing to market unapproved compounded GLP-1 products once the shortages that permitted broader compounding were resolved, on the grounds that it cannot verify the quality, safety or efficacy of those products. That position is about the compounding-pharmacy supply chain broadly, not a microdosing-specific ruling — but a microdosed product is, by definition, almost always a compounded one, so the same quality-and-verification gap applies to it directly.

The plausible mechanism-based risk

Receptor pharmacology gives a reason for caution that doesn't require a trial to state: a sub-threshold dose sustained over time is a different exposure pattern than either a full therapeutic dose or no drug at all, and it is not the pattern any GLP-1 receptor agonist has been studied under. Whether that produces reduced effectiveness, a different side-effect profile, or no meaningful difference at all is exactly the kind of question a trial would normally answer — and here, none has.

The practical takeaway

If cost is the reason microdosing is on the table, a fully-dosed but cheaper provider is a more evidence-grounded way to solve that problem than an untested dose — see best GLP-1 provider by need for the budget-focused picks, or the strictly price-sorted cheapest GLP-1 board. If side effects are the reason, both FDA labels already build a slow titration schedule into the approved dosing specifically to manage that — see GLP-1 dosage and titration schedules — and raising tolerability concerns with your prescriber is a lower-risk lever than dosing below label on your own.